Mayo Clin Proc. 2003 Aug;78(8):1020-4; quiz 1024.

Bupropion sustained release for treatment of tobacco dependence.

Source

Division of General Internal Medicine , Mayo Clinic, Rochester, Minn 55905, USA. hays.taylor@mayo.edu

Abstract

Tobacco use is a global pandemic. The most common pharmacological treatments of tobacco use and dependence include nicotine replacement therapy and nonnicotine medications. Bupropion sustained release (SR) is the only first-line nonnicotine medication recommended by the US Public Health Service Clinical Practice Guideline. Randomized controlled clinical trials have shown that bupropion SR doubles abstinence rates compared with placebo. Long-term treatment with bupropion SR may reduce or delay smoking relapse. Bupropion SR has an excellent adverse effect profile, although a risk exists for serious adverse effects such as seizures. The risk of serious adverse effects associated with bupropion SR can be reduced by careful selection of patients. This article reviews the evidence of efficacy and common adverse effects of bupropion SR and delineates the clinical characteristics of patients at higher risk for adverse effects when bupropion SR is prescribed for treatment of tobacco use and dependence.

PMID:: 12911050; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

MeSH Terms

Substances

Grant Support

R25 CA86421/CA/NCI NIH HHS/United States

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Molecular Biology Databases

BUPROPION HYDROCHLORIDE - HSDB

Supplemental Content

Save items

Related citations in PubMed

Review Bupropion for the treatment of tobacco dependence: guidelines for balancing risks and benefits. [CNS Drugs. 2003]
Review Bupropion for the treatment of tobacco dependence: guidelines for balancing risks and benefits.
Hays JT, Ebbert JO. CNS Drugs. 2003; 17(2):71-83.
Review Bupropion: a review of its use in the management of smoking cessation. [Drugs. 2000]
Review Bupropion: a review of its use in the management of smoking cessation.
Holm KJ, Spencer CM. Drugs. 2000 Apr; 59(4):1007-24.
Review Adverse effects and tolerability of medications for the treatment of tobacco use and dependence. [Drugs. 2010]
Review Adverse effects and tolerability of medications for the treatment of tobacco use and dependence.
Hays JT, Ebbert JO. Drugs. 2010 Dec 24; 70(18):2357-72.
Review Efficacy and safety of bupropion SR for smoking cessation: data from clinical trials and five years of postmarketing experience. [Int J Clin Pract. 2003]
Review Efficacy and safety of bupropion SR for smoking cessation: data from clinical trials and five years of postmarketing experience.
Ferry L, Johnston JA. Int J Clin Pract. 2003 Apr; 57(3):224-30.
Review Clinical efficacy of bupropion in the management of smoking cessation. [Drugs. 2002]
Review Clinical efficacy of bupropion in the management of smoking cessation.
Jorenby D. Drugs. 2002; 62 Suppl 2:25-35.

See reviews... See all...

Cited by 3 PubMed Central articles

Review Comparison of available treatments for tobacco addiction. [Curr Psychiatry Rep. 2010]
Review Comparison of available treatments for tobacco addiction.
Herman AI, Sofuoglu M. Curr Psychiatry Rep. 2010 Oct; 12(5):433-40.
A randomized clinical trial of St. John's wort for smoking cessation. [J Altern Complement Med. 2010]
A randomized clinical trial of St. John's wort for smoking cessation.
Sood A, Ebbert JO, Prasad K, Croghan IT, Bauer B, Schroeder DR. J Altern Complement Med. 2010 Jul; 16(7):761-7.
Bupropion and cognitive behavioral therapy for weight-concerned women smokers. [Arch Intern Med. 2010]
Bupropion and cognitive behavioral therapy for weight-concerned women smokers.
Levine MD, Perkins KA, Kalarchian MA, Cheng Y, Houck PR, Slane JD, Marcus MD. Arch Intern Med. 2010 Mar 22; 170(6):543-50.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
BioSystems
Pathways and biological systems (BioSystems) that cite the current articles. Citations are from the BioSystems source databases (KEGG and BioCyc).
Compound
PubChem chemical compound records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records. Multiple substance records may contribute to the PubChem compound record.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance
PubChem chemical substance records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Bupropion sustained release for treatment of tobacco dependence.
Bupropion sustained release for treatment of tobacco dependence.
Mayo Clin Proc. 2003 Aug ;78(8):1020-4; quiz 1024.

PubMed
Meta-analysis of dyspepsia and nonsteroidal antiinflammatory drugs.
Meta-analysis of dyspepsia and nonsteroidal antiinflammatory drugs.
Arthritis Rheum. 2003 Aug 15 ;49(4):508-18.

PubMed
Characterization of a supernumerary ring chromosome 1 mosaicism in two cell syst...
Characterization of a supernumerary ring chromosome 1 mosaicism in two cell systems by molecular cytogenetic techniques and review of the literature.
Am J Med Genet A. 2003 Aug 30 ;121A(2):163-7.

PubMed
How well can we predict native contacts in proteins based on decoy structures an...
How well can we predict native contacts in proteins based on decoy structures and their energies?
Proteins. 2003 Sep 1 ;52(4):598-608.

PubMed
[Neurological complications of inflammatory intestinal diseases].
[Neurological complications of inflammatory intestinal diseases].
Fortschr Neurol Psychiatr. 2003 Aug ;71(8):406-14.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: